Literature DB >> 20420641

Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis.

J Sint Nicolaas1, V De Jonge1, E W Steyerberg2, E J Kuipers1,3, M E Van Leerdam1, S J O Veldhuyzen-van Zanten4.   

Abstract

Liver transplant patients (LTx) have an increased risk for developing de novo malignancies, but for colorectal cancer (CRC) this risk is less clear. We aimed to determine whether the CRC risk post-LTx was increased. A systematic search was performed in MEDLINE and Cochrane databases to identify studies published between 1986 and 2008 reporting on the risk of CRC post-LTx. The outcomes were (1) CRC incidence rate (IR per 100,000 person-years (PY)) compared to a weighted age-matched control population using SEER and (2) relative risk (RR) for CRC compared to the general population. If no RR data were available, the RR was estimated using SEER. Twenty-nine studies were included. The overall post-LTx IR was 119 (95% CI 88-161) per 100,000 PY. The overall RR was 2.6 (95% CI 1.7-4.1). The non-primary sclerosing cholangitis (PSC) IR was 129 per 100,000 PY (95% CI 81-207). Compared to SEER (71 per 100,000 PY), the non-PSC RR was 1.8 (95% CI 1.1-2.9). In conclusion, the overall transplants and the subgroup non-PSC transplants have an increased CRC risk compared to the general population. However, in contrast to PSC, non-PSC transplants do not need an intensified screening strategy compared to the general population until a prospective study further defines recommendations.

Entities:  

Mesh:

Year:  2010        PMID: 20420641     DOI: 10.1111/j.1600-6143.2010.03049.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  17 in total

Review 1.  Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.

Authors:  Christophe Carenco; Stéphanie Faure; José Ursic-Bedoya; Astrid Herrero; Georges Philippe Pageaux
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation.

Authors:  Birju D Bhatt; Thresiamma Lukose; Abby B Siegel; Robert S Brown; Elizabeth C Verna
Journal:  J Gastrointest Oncol       Date:  2015-10

3.  A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation.

Authors:  Veena Nannegari; Saenz Roque; David T Rubin; Rodrigo Quera
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

Review 4.  Screening for malignancy in primary sclerosing cholangitis (PSC).

Authors:  Saira A Khaderi; Norman L Sussman
Journal:  Curr Gastroenterol Rep       Date:  2015-04

5.  Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat.

Authors:  Giulia Bonato; Laura Cristoferi; Mario Strazzabosco; Luca Fabris
Journal:  Dig Dis       Date:  2015-12-07       Impact factor: 2.404

Review 6.  Neoplastic disease after liver transplantation: Focus on de novo neoplasms.

Authors:  Patrizia Burra; Kryssia I Rodriguez-Castro
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

7.  The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease.

Authors:  Mahmoud Mosli; Kristopher Croome; Karim Qumosani; Bandar Al-Judaibi; Melanie Beaton; Paul Marotta; Natasha Chandok
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-07

8.  Colorectal Resection in Transplant Centers Benefits Kidney But Not Pancreas Transplant Recipients.

Authors:  Lauren Weaver; Afshin Parsikia; Jorge Ortiz
Journal:  Int J Angiol       Date:  2021-05-13

9.  Increased incidence of head and neck cancer in liver transplant recipients: a meta-analysis.

Authors:  Qian Liu; Lifeng Yan; Cheng Xu; Aihua Gu; Peng Zhao; Zhao-Yan Jiang
Journal:  BMC Cancer       Date:  2014-10-22       Impact factor: 4.430

Review 10.  Inflammatory bowel disease in liver transplanted patients.

Authors:  Tajana Filipec Kanizaj; Maja Mijic
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.